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Gate Array) device and few satellite discrete electronic 
components. An additional advantage of the FPGA solution is 
a very low cost. At present, in the prototype phase, one 
sample together with digitization costs only about 10 Euro.  
Results: The proposed solution provides very good time 
measurement properties, allowing to probe the signal in the 
voltage domain with an accuracy below 20 ps (σ) [5]. The 
input signals are amplified and split into four paths, each 
having an individual threshold level. This multi-level 
threshold technique is well suited for the application of 
reconstruction methods of the hit position of gamma quanta 
in the scintillator, which results in the improvement of the 
TOF resolution. We developed several hit reconstruction 
methods, e.g. compressive sensing technique allows for the 
recovery of the full signal shape and amplitude based on the 
samples registered in the PMTs. This information can be used 
to improve the precision of the hit position reconstruction 
[6]. Other methods are based on the comparison of detector 
signals with results stored in a library of synchronized model 
signals registered for a set of well-defined positions of 
scintillation points. The hit position is reconstructed as the 
one corresponding to the signal from the library, which is 
more similar to the measurement signal. A degree of 
similarity between measured and model signals is defined as 
the distance between points representing the measurement- 
and model-signal in a multidimensional measurement space 
[7] or as the Mahalonobis distance[8]. 
In this talk, the developed front-end electronics will be 
described. Also, the application of the multi-threshold 
measurement to the hit reconstruction methods will be 
presented. 
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Purpose: In intensity modulated proton therapy (IMPT), inter-
fractional anatomical changes can substantially compromise 
the treatment quality for cranial and pelvic lesions [1,2], 
motivating treatment adaptation. The increasing availability 
of in-room cone beam computed tomography (CBCT) in 
proton centers enables frequent acquisition of 3D imaging 
data which may be used for dose calculation and plan 
adaptation. This work investigates and compares two 
complementary approaches for correcting CBCT image 
intensity for dose calculation in adaptive IMPT for head and 
neck (H&N) and prostate cancer. For H&N patients a mid-
treatment replanning CT was used for validating the 
correction methods. 
Material and methods: CBCT images and corresponding 
projections of 3 H&N and 3 prostate cancer patients were 
used in this study. In the first approach, a so-called virtual 
CT (vCT) was generated by deformable image registration 
(DIR) of the corresponding planning CT to the pre-treatment 
CBCT [3]. In the second approach, the vCT was used as prior 
for scatter correction of the raw CBCT projections, following 
the approach of Park et al.[4] Reconstruction of the 
corrected projections yielded a corrected CBCT image 
(CBCTcor). Both approaches were evaluated for CT number 
accuracy using phantom scans and compared by means of 
beam eye view 2D range maps of single field uniform dose 
(SFUD) plans in all patients. For prostate cases, the 
geometric accuracy of target and OAR structures was also 
evaluated qualitatively. 
Results: For H&N cases, no considerable differences between 
SFUD dose calculations on vCT and CBCTcor were found, with 
97.3% to 99.8% of the 2D range maps showing a range 
difference below 3 mm (Table 1). Median range differences 
compared to a diagnostic quality replanning CT acquired 
within 3 days of the CBCT were below 0.5 mm. For prostate 
cases, an even higher agreement of SFUD beam ranges 
between vCT and CBCTcor was observed (Table 1). However, 
the analysis also showed that the DIR-based vCT approach 
exhibits inaccuracies in the pelvic region due to the very low 
soft-tissue contrast in the CBCT. The CBCTcor approach 
yielded results closer to the original CBCT (Figure 1), 
promising an improved accuracy in delineation. In general, 
the CBCTcor approach was not affected by inaccuracies of the 
DIR used during the generation of the vCT prior. An enhanced 
agreement of bowel filling with respect to the original CBCT 
image was observed on the CBCTcor. 
Conclusions: A DIR-based CBCT intensity correction has been 
compared to a scatter correction method on basis of the 
CBCT projections. Both techniques yield 3D CBCT images with 
intensities equivalent to diagnostic CT and appear to be 
suitable for dose calculation in adaptive IMPT. For H&N 
cases, no considerable differences between the two 
techniques were found, while improved results of the CBCTcor 
were observed for pelvic cases due to the reduced sensitivity 
to registration inaccuracies. A detailed quantification based 
on delineation accuracy using vCT and CBCTcor is under way. 
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Table 1: SFUD BEV range comparison of vCT and CBCTcor for 
the investigated H&N (PatHN1-3) and prostate (PatPR1-3) 
patients. The percentage of 2D range maps with a range 
difference (RD) below 3mm and 2mm is given together with 
the median range difference and half the 2.5% to 97.5% inter-
percentile range (IPR). The SFUD angle is given according to 
the IEC scale.  
 
 
Figure 3: Comparison of vCT, CBCTcor, initial planning CT 
(pCT) and the original CBCT of PatPR3, using the same 
window for displaying. The original CBCT shows inaccurate 
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CT numbers, thus demonstrating the need for CBCT 
corrections as investigated in this work. The DIR inaccurately 
matches the outline of the bladder (see dashed circle), 
leading to a wrong anatomy in the vCT. In contrast, the 
CBCTcor bladder anatomy agrees well with the original CBCT.  
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Its excellent soft tissue contrast makes MRI extremely well 
suited for guidance of external beam radiotherapy.  
In recent years, using cone beam CT-linac radiotherapy 
systems, great success has been realized in the minimal 
invasive treatment of prostate tumours, stereotactic ablative 
body radiotherapy of lung tumours and stereotactic 
treatment of tumours of the brain. For these tumours, there 
is good visualization of the tumour itself or there is a good 
visualization of tumour related structures or fiducial markers. 
There is a clear trend towards better targeting with less 
normal tissue involvement and thus less toxicity, less surgery 
and less fractionation. However, for most other tumour 
locations the limited visualization using cone beam CT and 
the lack of dynamic information hinders this development. 
On-line and real-time MRI guidance may offer the possibility 
to implemented this stereotactic revolution for most 
remaining tumour locations like radiotherapy of tumours of 
the rectum, oesophagus, pancreas, kidney, individual lymph 
nodes, etc. This may provide a breakthrough in the 
application of radiotherapy and redefine the relation 
radiotherapy and surgery.  
Essential is the availability of high quality MRI (e.g.1.5T 
Philips Ingenia) during the actual treatment process. The 
design of the experimental UMCUtrecht/Elekta MRI-Linac 
combination has been described in Lagendijk et al. [2008] 
and Raaymakers et al. (2009). The MRI accelerator facilitates 
good soft tissue visualization and continuous patient anatomy 
updates regarding translations, rotations and deformations of 
targets and organs at risk. Accounting for this, demands high 
speed, online intensity-modulated radiotherapy re-
optimization. The MRI must supply real-time information 
about the actual position of the tumour and organs at risk 
and the on-line treatment planning must be able to deal with 
this. Dedicated sequences and correction protocols are being 
developed to guarantee extreme fast and geometrically 
correct MR imaging. Essential is that the complete 3D 
anatomy can be followed in real-time. Treatment planning 
procedures are being developed which can optimize the dose 
delivered on the actual anatomy. 
The radiation dose is being delivered with the patient in a 
1.5T magnetic field. The actual dose deposition, beam 
characteristics and absolute dosimetry must be evaluated for 
this magnetic field environment. 
The clinical introduction of the MRL system is being 
organized within an international consortium. Within this 
consortium structure imaging protocols are being optimizes, 
‘blue sky’ approached are being discussed for several tumour 
groups and the actual clinical trials are being designed. 
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In 2009, the Health Council of Ministry of Health published 
the Horizon Scanning Report Proton Radiotherapy, which 
paved the way for the clinical introduction of proton therapy 
in the Netherlands. In this report, four categories of 
indications were identified, including: standard indications 
(e.g. pediatric patients), prevention of secondary tumors in 
young patients with favorable prognosis (e.g. Hodgkin 
lymphoma), potential indications (i.e. dose escalation 
without enhancing toxicity) and the model-based indications 
(i.e. prevention of side effects). The model-based indications 
are the largest group of indications. In this category, patients 
will only be selected for proton therapy after an individual 
planning comparison and if the difference in dose translates 
in a minimal difference in NTCP (ΔNTCP). This model-based 
approach has been recognized by the Health Insurance Board 
as well, which means that patients selected for proton 
therapy according to this approach will receive 
reimbursement for their treatment. 
In addition to this, the Ministry of Health, together with the 
proton therapy initiatives launched a national plan for proton 
therapy, which includes the realization of four small to 
medium sized proton therapy centers, with a geographic 
distribution over the country that foresees optimal 
accessibility of proton therapy for all eligible patients in the 
Netherlands. The maximum capacity to be created is 2,200 
patients per year, divided among these four centers. These 
centers are now under construction. 
Consensus has been reached on a national level regarding the 
threshold for ΔNTCP to be selected for proton therapy. More 
detailed indication protocols are now developed coordinated 
by the National Proton Therapy Platform, in which all 
radiotherapy departments are represented.  
In addition, the four initiatives closely collaborate to create 
a national prospective data registry program to create a 
rapid learning health care system which can be used to 
develop and externally validate NTCP-models and to validate 
the added value of proton therapy to reduce radiation-
induced side effects. 
In this way, the Netherlands is one of the first countries 
worldwide that will realize a well balanced national plan for 
proton therapy in which this new technology will be 
integrated in a multicenter clinical research environment.  
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Purpose: In 2005, the word “theranostics” was used for the 
first time for describing the use of imaging for therapy 
planning in radiation oncology. It is defined as the use of 
individual patient-level biological information in choosing the 
optimal therapy for that individual [1]. In Nuclear Medicine 
this term describes the use of short-lived tracers for 
predicting the absorbed doses in molecular radiotherapy and, 
thus, safety and efficacy of a treatment. 
Materials/Methods: For pre-therapeutic dosimetry for the 
purpose of dose-planning or for post-therapeutic dose 
verification, quantitative imaging of the biokinetics of the 
administered radiolabelled substance is necessary followed 
by the calculation of the absorbed doses with potential 
inclusion of biological effects. This comprises the following 
three steps: 
a) Quantitative Imaging 
The established method for quantitative imaging for 
dosimetry relies on the measurement of the biokinetics 
by serial PET/CT, SPECT/CT or whole body scan. For 
